Our study has several limitations. Although similar techniques were implemented in both study periods, possible confounding elements, such as changes in health care and in other vectorborne infections, weren’t measured, and we did not control for pooling of data from individual cohorts in this scholarly study. Moreover, estimates of the prevalence of malaria among females undergoing malaria-prevention methods at the hospital may not be representative of the prevalence locally at large. In conclusion, this research shows a rise in malaria with increased parasite densities and a larger adverse clinical effect following a marked fall in the prevalence of malaria and antimalarial immunity among pregnant women.All participants provided written informed consent. Roche sponsored the trial and gathered and analyzed the data. The lead writer was involved in the style of the trial and evaluation of the data and vouches for the precision and completeness of the data. One academic and one industry writer wrote the initial draft of the manuscript; all authors contributed to subsequent drafts. Study Design This trial was a prospective, multicenter, open-label, nonrandomized study of treatment with peginterferon alfa-2a in Latino and non-Latino whites with chronic HCV genotype 1 infection who had not previously received treatment. Assessments of virologic and biochemical responses were performed at weeks 4, 12, 24, 48, 60, and 72. Clinical adverse events, laboratory ideals, vital signs, and dose adjustments of the scholarly research drugs were monitored through the entire study.